[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566077":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":45,"responsibleParty":72,"collaborators":26,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":26,"enrollmentInfo":85,"targetDuration":26,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Change to clopidogrel","EXPERIMENTAL","Patients will have their aspirin discontinued and start clopidogrel.",[13],"Drug: Clopidogrel",{"label":15,"type":16,"description":17,"interventionNames":18},"Continue aspirin","ACTIVE_COMPARATOR","Patients will continue their existing aspirin",[19],"Drug: Aspirin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Clopidogrel","Patients will change from aspirin to clopidogrel (without loading dose)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Aspirin","Patients will continue their existing aspirin.",[15],[32,36],{"name":33,"affiliation":34,"role":35},"Todd C Lee, MD MPH FIDSA","Research Institute of the McGill University Health Centre","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":34,"role":35},"Emily G McDonald, MD MSc",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Lina Petrella","CONTACT","5149341934","23730","lina.petrella@muhc.mcgill.ca",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)","RECRUITING","Montreal","Quebec","H4A3S1","Canada","CA",{"type":55,"coordinates":56},"Point",[57,58],-73.58781,45.50884,{"lat":58,"lon":57},[61,63,64,65,68,70],{"name":40,"role":41,"phone":62,"phoneExt":43,"email":44},"514-934-1934",{"name":33,"role":35,"phone":26,"phoneExt":26,"email":26},{"name":37,"role":35,"phone":26,"phoneExt":26,"email":26},{"name":66,"role":67,"phone":26,"phoneExt":26,"email":26},"Matthew P. Cheng, MD SM","SUB_INVESTIGATOR",{"name":69,"role":67,"phone":26,"phoneExt":26,"email":26},"Patrick Lawler, MD MPH",{"name":71,"role":67,"phone":26,"phoneExt":26,"email":26},"Alexander Lawandi, MD MSc",{"type":73,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Todd C. Lee MD MPH FIDSA","Associate Professor of Medicine and Staff Scientist","100566077","phase-4-clopidogrel-vs-aspirin-for-cardiovascular-risk-reduction-in-patients-with-s-aureus-bacteremia-100566077",false,"NCT06650488","Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia","Clopido-SNAP 2","The participant must meet all inclusion and exclusion criteria for the SNAP\n\nPlatform (NCT05137119) and also the following inclusion and exclusion criteria:\n\nInclusion Criteria:\n\n* Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)\n\nExclusion Criteria:\n\n* Active bleeding (allowing up to 3 days from platform entry to randomize in the event anti-thrombotic therapy is resumed)\n* Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days\n* Pregnancy\n* Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month\n* Allergy to clopidogrel\n* Concomitant receipt of oral Xa inhibitor","ALL","18 Years",{"count":86,"type":87},300,"ESTIMATED","INTERVENTIONAL",[90],"PHASE4","This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.\n\nUnlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.\n\nThis study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).\n\nIf positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.",[93,94,95],"Staphylococcus Aureus Endocarditis","Staphylococcus Aureus Septicemia","Staphylococcus Aureus Bloodstream Infection",[97,98,99,100,101],"S. aureus bactremia","S. aureus bloodstream infection","S. aureus endocarditis","aspirin","clopidogrel","2026-03-17",{"date":104,"type":105},"2026-03-20","ACTUAL",{"date":107,"type":105},"2026-01-15",{"date":109,"type":87},"2030-01",{"name":74,"class":6},1]